This research focuses on the
use of cyclooxygenase-2 (COX-2) inhibitor and proton pump
inhibitor drugs (PPIs) for cancer chemoprevention in Barrett¹s.
A clinical trial studying the effectiveness of COX-2 inhibitors
at lowering COX-2 protein expression in oesophageal tissue
has raised the possibility of two new variants of COX-2. This
work is being extended with more 2D proteomic investigations
being undertaken which will allow confirmation of the previously
unidentified proteins. Another functional pharmacoproteomic
study is being conducted which is examining proteins in oesophageal
tissue from patients treated with PPIs where diseased tissue
has regressed with the objective of identifying potentially
important diagnostic proteins involved in the pathogenesis
of Barrett¹s oesophagus.
